NASDAQ:UBX

Unity Biotechnology Stock Forecast, Price & News

$4.46

-0.25 (-5.31 %)

(As of 06/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.45

▼

$4.75

50-Day Range

$4.20

▼

$5.89

52-Week Range

$2.72

▼

$15.44

Volume394,282 shs

Average Volume631,795 shs

Market Capitalization$244.65 million

P/E RatioN/A

Dividend YieldN/A

Beta0.24

30 days | 90 days | 365 days | Advanced Chart

Receive UBX News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

About Unity Biotechnology

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Is Unity Biotechnology, Inc. (NASDAQ:UBX) Popular Amongst Institutions?
June 8, 2021 | finance.yahoo.com

HC Wainwright Begins Coverage on Unity Biotechnology (NASDAQ:UBX)
June 7, 2021 | americanbankingnews.com

Zacks: Analysts Expect Unity Biotechnology, Inc. (NASDAQ:UBX) Will Post Earnings of -$0.33 Per Share
June 4, 2021 | americanbankingnews.com

Unity Biotechnology, Inc. (NASDAQ:UBX) Receives Average Recommendation of "Hold" from Analysts
May 24, 2021 | americanbankingnews.com

How Much Are Unity Biotechnology, Inc. (NASDAQ:UBX) Insiders Taking Off The Table?
May 13, 2021 | nasdaq.com

UNITY Biotechnology, Inc. Reports First Quarter 2021 Financial Results and Business Updates
May 11, 2021 | finance.yahoo.com

UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseases
May 1, 2021 | finance.yahoo.com

UNITY Biotechnology to Present Preclinical Data on Clinical Candidate Molecule UBX1325 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
April 28, 2021 | finance.yahoo.com

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Business Updates
March 23, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:UBX
Previous Symbol
CUSIPN/A
CIK1463361
Webwww.unitybiotechnology.com
Phone650 416 1192
Employees63
Year FoundedN/A

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares54,855,000
Market Cap$244.65 million
Next Earnings Date7/30/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.39 out of 5 stars

Medical Sector

746th out of 2,100 stocks

3.0 Analyst's Opinion

Consensus Rating
Unity Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Unity Biotechnology has a forecasted upside of 34.5% from its current price of $4.46.
Amount of Analyst Coverage
Unity Biotechnology has only been the subject of 2 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Unity Biotechnology has received 148 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Unity Biotechnology has received 145 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Unity Biotechnology has received 50.51% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Unity Biotechnology and other stocks. Vote “Outperform” if you believe UBX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe UBX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Unity Biotechnology does not currently pay a dividend.
Dividend Growth
Unity Biotechnology does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Unity Biotechnology insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.80% of the stock of Unity Biotechnology is held by insiders.
Percentage Held by Institutions
37.01% of the stock of Unity Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Unity Biotechnology are expected to grow in the coming year, from ($1.43) to ($1.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Unity Biotechnology is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Unity Biotechnology is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions

Is Unity Biotechnology a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Unity Biotechnology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in UBX, but not buy additional shares or sell existing shares.
View analyst ratings for Unity Biotechnology or view top-rated stocks.

What stocks does MarketBeat like better than Unity Biotechnology?

Wall Street analysts have given Unity Biotechnology a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Unity Biotechnology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Unity Biotechnology's next earnings date?

Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Friday, July 30th 2021.
View our earnings forecast for Unity Biotechnology.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology, Inc. (NASDAQ:UBX) issued its quarterly earnings data on Wednesday, May, 12th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.09.
View Unity Biotechnology's earnings history.

How has Unity Biotechnology's stock been impacted by COVID-19 (Coronavirus)?

Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, UBX shares have decreased by 17.3% and is now trading at $4.46.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for UBX?

6 brokerages have issued 1 year price objectives for Unity Biotechnology's shares. Their forecasts range from $4.00 to $12.00. On average, they expect Unity Biotechnology's share price to reach $6.00 in the next year. This suggests a possible upside of 34.5% from the stock's current price.
View analysts' price targets for Unity Biotechnology or view top-rated stocks among Wall Street analysts.

Who are Unity Biotechnology's key executives?

Unity Biotechnology's management team includes the following people:

Dr. Anirvan Ghosh, CEO & Director (Age 57, Pay $758.57k)
Ms. Lynne Marie Sullivan, CFO & Head of Corp. Devel. (Age 55, Pay $471.36k)
Dr. Jamie Dananberg, Chief Medical Officer (Age 63, Pay $625.59k)
Dr. Nathaniel E. David, Co-Founder & Exec. Director (Age 53)
Dr. Jan M. van Deursen, Founder
Dr. Judith Campisi, Founder
Mr. Daohong Zhou M.D., Founder
Mr. Nathan Guz Ph.D., VP of Operations
Mr. Alexander Azoy, VP of Fin., Chief Accounting Officer, Controller & Principal Accounting Officer (Age 45)
Dr. Przemyslaw Sapieha Ph.D., Chief Scientific Advisor

Who are some of Unity Biotechnology's key competitors?

Some companies that are related to Unity Biotechnology include AngioDynamics (ANGO), Trillium Therapeutics (TRIL), Apria (APR), Enanta Pharmaceuticals (ENTA), Vaxart (VXRT), Semperit Aktiengesellschaft (SEIGY), Amphastar Pharmaceuticals (AMPH), ViewRay (VRAY), Omeros (OMER), Aclaris Therapeutics (ACRS), iTeos Therapeutics (ITOS), Syndax Pharmaceuticals (SNDX), G1 Therapeutics (GTHX), BioXcel Therapeutics (BTAI) and OrganiGram (OGI).
View all of UBX's competitors.

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), (CGC), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.19%), Geode Capital Management LLC (1.01%), Northern Trust Corp (0.67%), Russell Investments Group Ltd. (0.34%), Morgan Stanley (0.31%) and Nuveen Asset Management LLC (0.25%).
View institutional ownership trends for Unity Biotechnology.

Which major investors are selling Unity Biotechnology stock?

UBX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Russell Investments Group Ltd., Goldman Sachs Group Inc., BlackRock Inc., Saturna Capital CORP, Northern Trust Corp, Squarepoint Ops LLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Unity Biotechnology or view top insider-selling stocks.

Which major investors are buying Unity Biotechnology stock?

UBX stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Dimensional Fund Advisors LP, Ballentine Partners LLC, Cubist Systematic Strategies LLC, Nuveen Asset Management LLC, JPMorgan Chase & Co., Barclays PLC, and Alliancebernstein L.P..
View insider buying and selling activity for Unity Biotechnology or or view top insider-buying stocks.

How do I buy shares of Unity Biotechnology?

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $4.46.

How much money does Unity Biotechnology make?

Unity Biotechnology has a market capitalization of $244.65 million.

How many employees does Unity Biotechnology have?

Unity Biotechnology employs 63 workers across the globe.

What is Unity Biotechnology's official website?

The official website for Unity Biotechnology is www.unitybiotechnology.com.

How can I contact Unity Biotechnology?

The company can be reached via phone at 650 416 1192.

This page was last updated on 6/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here